CONMED (CNMD)
(Real Time Quote from BATS)
$70.43 USD
-0.76 (-1.07%)
Updated Nov 15, 2024 11:44 AM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Price, Consensus and EPS Surprise
CNMD 70.43 -0.76(-1.07%)
Will CNMD be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CNMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CNMD
Conmed (CNMD) is a Top-Ranked Momentum Stock: Should You Buy?
Why Conmed (CNMD) is a Top Value Stock for the Long-Term
CNMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Conmed (CNMD) is a Strong Growth Stock
CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View
Conmed (CNMD) Reports Q3 Earnings: What Key Metrics Have to Say
Other News for CNMD
Election 2024: Where To Put Your Money Following the Vote
EARNEST PARTNERS LLC Adjusts Stake in Conmed Corp
Capital Research Global Investors Adjusts Stake in Conmed Corp
CNMD Makes Bullish Cross Above Critical Moving Average
Stifel Nicolaus Sticks to Its Buy Rating for Conmed (CNMD)